Oppenheimer has downgraded Edwards Lifesciences Corp (EW) to Perform from Outperform as of October 7, 2025. The stock is currently priced at $84.78.
This revision reflects increased caution regarding the company's outlook, potentially due to competitive pressures, market conditions, or execution risks that could affect performance.
Edwards Lifesciences, headquartered in Irvine, California, focuses on patient-centered medical innovations for heart disease and critical care monitoring. The company has a market capitalization of $49.5 billion and a P/E ratio of 36.20, with an EPS of 2.33. Its product offerings include Transcatheter Aortic Valve Replacement (TAVR) technologies and Transcatheter Mitral and Tricuspid Therapies (TMTT).
Upcoming earnings are scheduled for July 22, 2026, with an estimated EPS of $0.75 and revenue of $1.7 billion. Analyst consensus indicates 10 Strong Buy, 18 Buy, and 15 Hold ratings, with a consensus rating of Buy as of November 1, 2025. Recent analyst actions also include an upgrade from Evercore ISI Group to Outperform on the same day as the downgrade from Oppenheimer.
Investors should consider various factors, including company fundamentals and industry trends, in their decision-making process. Analyst ratings are subject to change as new information becomes available, and differing opinions may exist across analysts.